The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Targeting the uncommon alterations in CRC
Andrea Sartore-Bianchi, MD, ASST Great Niguarda Metropolitan Hospital, Milan, discusses targeting uncommon alterations in colorectal cancer (CRC), including HER2 amplifications, KRASG12C mutations and alterations in NTRK, ALK and RET genes. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH
